- Home
- ACHV vs SERA Comparison
ACHV vs SERA Comparison
Compare ACHV & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- SERA
- Stock Information
- Founded
- ACHV N/A
- SERA 2008
- Country
- ACHV United States
- SERA United States
- Employees
- ACHV N/A
- SERA N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SERA Precision Instruments
- Sector
- ACHV Health Care
- SERA Health Care
- Exchange
- ACHV Nasdaq
- SERA Nasdaq
- Market Cap
- ACHV 72.5M
- SERA 70.4M
- IPO Year
- ACHV N/A
- SERA 2021
- Fundamental
- Price
- ACHV $2.23
- SERA $2.58
- Analyst Decision
- ACHV Strong Buy
- SERA
- Analyst Count
- ACHV 3
- SERA 0
- Target Price
- ACHV $14.33
- SERA N/A
- AVG Volume (30 Days)
- ACHV 1.2M
- SERA 808.0K
- Earning Date
- ACHV 08-12-2025
- SERA 08-06-2025
- Dividend Yield
- ACHV N/A
- SERA N/A
- EPS Growth
- ACHV N/A
- SERA N/A
- EPS
- ACHV N/A
- SERA N/A
- Revenue
- ACHV N/A
- SERA $115,000.00
- Revenue This Year
- ACHV N/A
- SERA $390.13
- Revenue Next Year
- ACHV N/A
- SERA $440.54
- P/E Ratio
- ACHV N/A
- SERA N/A
- Revenue Growth
- ACHV N/A
- SERA N/A
- 52 Week Low
- ACHV $1.84
- SERA $1.37
- 52 Week High
- ACHV $5.31
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- ACHV 33.69
- SERA 55.80
- Support Level
- ACHV $2.00
- SERA $1.82
- Resistance Level
- ACHV $3.90
- SERA $4.09
- Average True Range (ATR)
- ACHV 0.29
- SERA 0.37
- MACD
- ACHV -0.18
- SERA 0.17
- Stochastic Oscillator
- ACHV 8.91
- SERA 44.92
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.